BeStock  
Stocks › Biotechnology › VRDN

Viridian Therapeutics VRDN

US equityMarket cap rank #2344Biotechnology
$29.96 −$1.48 (-4.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $29.96 0.00%
Open$31.12
Prev close$31.44
Day range$29.87 – $31.75
Volume1.75M
Market cap$3.40B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-8.0x
CheapRich

Near the bottom of its 5-year range · 12th percentile, 5-year average -4.9x

Price / book7.3x
CheapRich

Above its usual level · 76th percentile, 5-year average 6.0x

#4745 of 5330 stocks by PB (1 = cheapest)

Price / sales133.2x
CheapRich

Below its usual level · 21st percentile, 5-year average 1,839.3x

#4979 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-12x-8x-4x0xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$42.91
Price vs. fair value-30.2%Trading below the estimate
Star rating★★★★☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 7.26 – 6.00 76% (pricier than usual) #4745 of 5330 (1 = cheapest)
PE -8.02 -11.97 -4.91 12% (cheaper than usual) –
PS 133.25 11.41 1,839.27 21% (cheaper than usual) #4979 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on VRDN.

Sign in to join the discussion.

Scroll to Top